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Alzheimer’s disease (AD), the most common dementia, is characterized by potentially neurotoxic aggregation of Aβ
peptide and tau protein, and their deposition as amyloid plaques and neurofibrillary tangles (NFTs). Tau aggregation
also occurs in other common neurodegenerative diseases. Frontotemporal dementia (FTD) can be caused by tau
mutations that increase the susceptibility of tau to hyperphosphorylation and aggregation, which may cause neuronal
dysfunction and deposition of NFTs. 17-allylamino-17-demethoxygeldanamycin (17-AAG) is a potent inhibitor of heat
shock protein 90 (Hsp90), a cytosolic chaperone implicated in the proper folding and functions of a repertoire of client
proteins. 17-AAG binds to Hsp90 and enhances degradation of Hsp90 client protein. We sought to determine whether
17-AAG can reduce Aβ and tau pathology in the brains of AD and FTD model mice expressing Aβ or P301L mutant
tau, respectively. Mice were randomized to receive 25, 5, or 0 mg/kg 17-AAG thrice weekly from age eight to 11 months.
Analysis was performed by rotarod test on motor function, on the area occupied by plaques in hippocampus or NFTs
in medulla tissue sections, and on mortality. A high dose of 17-AAG tended to decrease NFTs in male mice (p = 0.08).
Further studies are required to confirm the effect of 17-AAG in diseases of tau aggregation.
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Abnormal aggregation of protein is a common theme
among neurodegenerative diseases: Aβ peptide in
Alzheimer’s Disease (AD), tau protein in AD and other
tauopathies such as some forms of frontotemporal demen-
tia (FTD), and α-synuclein in Parkinson’s disease and Lewy
Body Disease [1-4]. These serious diseases occur with a
high prevalence, yet no treatment is available to halt their
progression, and such treatments are urgently needed.
Drugs interfering with protein misfolding may hold prom-
ise for slowing neurodegenerative disease, as well as other
disorders of protein aggregation [5-7].
Extracellular amyloid plaques and intracellular neuro-
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stated.lesions found in Alzheimer’s disease [3]. Amyloid plaques
are mainly composed of Aβ, whereas NFTs consist of
hyperphosphorylated tau. Aβ aggregation in the brain par-
enchyma may initiate a series of events that eventually re-
sults in AD dementia [2]. These events include activation
of kinases that hyperphosphorylate tau, which may harm
neurons by direct toxicity of abnormal tau or by decreased
supply of tau to stabilize microtubules. Mutations in tau
can also cause such dysfunctions, leading to frontotem-
poral lobar degeneration (FTLD) [1].
Tg2576 and JNPL3 are mouse models of Aβ and tau
pathology, respectively [8,9]. Tg2576 mice contain the hu-
man APP gene with the Swedish mutation, leading to five-
fold and 14-fold higher than usual levels of Aβ1-40 and
Aβ1-42, respectively. Cognitive impairment develops at 9
to 10 months, with the presence of Aβ plaques in cortical
and limbic regions. JNPL3 mice contain human tau P301L
mutant protein, with expression controlled by the murineThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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tau products are generated in both human tauopathies and
JNPL3 mice [11]. This mutation causes motor and behav-
ioural deficits, plus NFTs, starting at 4.5 months of age, in
amygdala, medulla, cerebellum, hypothalamus, pons and
spinal cord [8].
Therapeutic approaches include reducing the brain con-
centrations of Aβ and tau or inhibiting their aggregation
[4,12,13]. Immunotherapy is being investigated as a method
for removing Aβ or tau, either in any form or in aggregated
forms. For example, JNPL3 mice immunized against tau
oligomers showed slower disease progression and fewer tau
aggregates than untreated mice [14]. It is possible that re-
moval of aggregation-prone proteins might be even more
effective if conducted before aggregation occurs, when the
proteins are still monomeric. But removing normal forms
of these proteins may disrupt their important cellular func-
tions. Aggregation-prone forms of proteins may be identi-
fied by their abnormally folded structure.
Heat shock proteins (HSPs) are chaperone proteins that
have the ability to remodel misfolded proteins or direct
them to the degradation pathway under either normal or
stress conditions. Since proteins must fold into precise
three-dimensional conformations to achieve their bio-
logical functions, HSPs assist cells to defend against exter-
nal stress, such as accumulation of misfolded proteins or
inflammation [15-17].
Heat shock protein 90 (Hsp90) is one of the most abun-
dant proteins in the cytosol of eukaryotic cells, accounting
for 1-2% of the total proteins under non-stress conditions
[18]. It has an essential role in the refolding of misfolded
proteins under stress [19]. Despite this, inappropriate signal
activation of Hsp90 could also occur during cellular stress
and lead to toxic protein aggregation [20]. Hsp90 binds to a
specific set of targets, which are known as Hsp90 client
proteins. It interacts with its client proteins in a dynamic
ATP dependent cycle to regulate folding and assembly of
its clients, but the mechanism is poorly understood.
Hsp90 consists of three domains, a highly conserved N-
terminal ATP-binding domain, a middle domain, and a
carboxyl domain. Both the N-terminal and C-terminal do-
mains play a role in preventing aggregation of denatured
proteins in vitro. By inhibiting the N-terminal ATP bind-
ing domain, the activity of Hsp90 is reduced [21], suggest-
ing that substrate binding is nucleotide regulated. Since
Hsp90 has a unique N-terminal ATP binding site, high
specificity inhibitors have been developed to inhibit the
ATP-dependent chaperone activities of Hsp90 [22].
17-N-Allylamino-17-demethoxygeldanamycin (17-AAG),
or tanespimycin, is a novel HSP90 inhibitor that has been
extensively studied for targeting oncoproteins [23]. It is a
less toxic derivative of geldanamycin (GA), a benzoquinoid
ansamycin compound produced by Streptomyces hygrosco-
picus that has growth inhibitory activity against tumours[24]. However, due to undesired toxicity, GA was not suit-
able for clinical studies. Instead, 17-AAG has been or is
now in clinical trials for a wide range of cancers. It is a can-
didate for treating neurodegenerative disorders.
17-AAG has two mechanisms of action. First, 17-AAG
disrupts the function of Hsp90 by binding to its ATP bind-
ing pocket, inhibiting the formation of the stabilizing form
and shifting the complex to the proteosome-targeting
form, which leads to proteosome degradation of client
protein [25]. Second, it inhibits the association of Hsp90
with heat shock factor-1, which results in transcription of
chaperones such as Hsp70 and Hsp40 [20,26,27]. These
two molecular chaperones act as protein quality control
units, refolding misfolded proteins or leading them to de-
struction. They use the energy gained from ATP hydroly-
sis to bind and remodel substrates under conditions either
with or without stress. Hsp70 requires assistance from
Hsp40 to facilitate substrate recognition and stimulate the
hydrolysis of ATP [28]. Induction of Hsp40 and Hsp70 by
geldanamycin successfully suppressed mutant huntingtin
in a Huntington’s disease cell model [20], suggesting the
possibility of geldanamycin or 17-AAG as treatments for
other neurodegenerative diseases involving protein mis-
folding. Waza et al. [15] tested 17-AAG to decrease mutant
androgen receptor (AR), a client protein of Hsp90 that
causes spinal and bulbar muscular atrophy (SBMA). Mu-
tant AR products in cell models were drastically decreased
after being treated by 17-AAG, even with complete inhib-
ition of Hsp70 and Hsp40, which was achieved by protein
synthesis inhibitor.
17-AAG might be used to block Aβ or tau aggregation.
Hsp70 helps prevent early stages of protein aggregation, in-
cluding that of Aβ [17]. It can function extracellularly [29]
and therefore might promote disaggregation of extracellu-
lar Aβ. Hsp90 may play a role in Aβ peptide aggregation
[17], and a non-toxic Hsp90 inhibitor significantly reduced
Aβ neurotoxicity in embryonic primary neurons [30]. By
targeting Hsp90, client proteins which are normally stabi-
lized by Hsp90 will be targeted for degradation [31]. There-
fore, 17-AAG could potentially act as a neuroprotective
agent that counters the toxic effects of Aβ by disrupting its
aggregation and promoting its clearance.
Inhibiting the action of Hsp90 may affect tau by several
possible mechanisms. Tau is a Hsp90 client protein [32].
Hyperphosphorylated tau binds with higher affinity to
Hsp90 than to normal tau [33]. Binding of hyperpho-
sphorylated tau to Hsp90 enhances stabilization and aggre-
gation [34,35], thus Hsp90 inhibition may reduce tau
aggregation. Extracellular signal-regulated protein kinase
(ERK) is an Hsp90 client protein, and 17-AAG is able to re-
duce the amount of and aggregation of phosphorylated tau,
possibly by inhibiting the action of ERK [36]. 17-AAG is
capable of inducing Hsp40 and Hsp70, of which Hsp70 was
seen to be able to reduce the level of tau [33,37]. In light of
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therapeutic agent for tauopathies such as FTLD.
17-AAG has excellent bioavailability after intraperito-
neal injection in mice [38], but oral bioavailability is poor.
It undergoes extensive hepatic metabolism by cytochrome
P450 (CYP) 3A4 and is widely distributed in body tissues
[38,39]. Preclinical toxicology studies showed that 17-
AAG has dose-limiting hepatic and gallbladder toxicity,
but it is less toxic than geldanamycin [40]. Studies on the
tissue distribution of 17-AAG in mice showed that it pen-
etrates the blood brain barrier [41,42].
In this study, we investigated the effect of 17-AAG on Aβ
aggregation in the Tg2576 transgenic mouse model of AD
and tau aggregation in the JNPL3 mouse model of FTLD.
We quantified the effects on several outcomes: mortality,
motor function, and plaque and tangle pathology.
Materials and methods
Animals
Mice that overexpress Aβ or a mutant tau protein were
bought from Taconic Farms, Inc. and were bred at the
Chinese University of Hong Kong for experiments. The
Chinese University of Hong Kong Animal Experimenta-
tion Ethics Committee approved the study. Tg2576 is a
transgenic mouse model that is hemizygous for the human
β-amyloid precursor protein gene with the Swedish muta-
tion (K670N/M671L) (APPswe), which leads to Aβ over-
expression. It was bred on F1 progeny of SJL/JcrNTac and
C57BL6/NTac strains. Tau transgenic mice (JNPL3) were
used as a tauopathy model. The mice are homozygous for
the 4R0N isoform of the human microtubule-associated
protein tau with the P301L mutation.
Rotarod test
Motor function deteriorates in JNPL3 mice as they age,
and this was assessed by rotarod test [43]. Four rounds
of trial training and one round of testing were performed
with a one hour interval in between. Mice were placed
onto the rod of the apparatus. Rotation was started at 4
revolutions per minute (rpm) to allow the mice to bal-
ance and then was increased by about 1 rpm/9 seconds,
to a maximum of 40 rpm. The time between the begin-
ning of the acceleration of the rod and the falling of each
mouse was recorded.
The time that each mouse could stay on the rotarod was
measured three times before treatment and three times at
the end of treatment. The three before-treatment times
were averaged, as were the three after-treatment times. For
mice that died during treatment, after-treatment time was
assigned as missing rather than 0. These averaged times
were then used as the outcome variable in a longitudinal
data analysis using linear mixed models (multilevel models).
The predictor variables were dose (0, 5, 25), condition (be-
fore treatment, after treatment), and the interactionbetween dose and condition. The interaction terms esti-
mate the effect of the treatment, as they represent the dif-
ference between the dosage groups in change in times
before and after treatment. Sex was also originally entered
into the models but was found not to be a significant pre-
dictor of effect modifier. We analyzed the data again using
a longitudinal analysis method (linear mixed model) which
allows the use of all of the available times even when there
is only one time for a mouse. This method models each
time as a function of condition (before or after treatment),
dose (0, 5, 25), and a condition x dose interaction. The
interaction is essentially what tests the effectiveness of dose
since it represents the difference between before and after
times among the different dosage groups.
Treatment with 17-AAG
Doses of 17-AAG were chosen based on a study to treat
spinal and bulbar muscular atrophy in mice [15]. In that
study, 2.5 mg/kg and 25 mg/kg 17-AAG were used, with
25 mg/kg producing better protection. Since the optimum
dose was therefore likely closer to 25 mg/kg than to
2.5 mg/kg, we increased the lower dose for our study,
choosing a level of 5 mg/kg.
17-AAG (Fermentek, Israel) was prepared as a 50 mg/ml
stock solution in DMSO. Starting at age eight months, 48
Tg2576 and 94 JNPL3 mice were treated with 25, 5, or
0 mg/kg of 17-AAG in 100% DMSO (2 ml/kg) by thrice
weekly intraperitoneal injections for 3 months before being
sacrificed.
Brain sample preparation
Mice were killed, and brains were removed and split into
hemispheres. One hemisphere was immediately immersed
in 13 mL ice-cold 10% neutral buffered formalin (10%
NBF) and incubated at 4°C overnight. Fixed brains were
processed according to standard immunohistochemical
procedure. Paraffin sections of 8 μm were prepared from
hippocampus, -1.7 mm to -.3 mm from the bregma, and
from medulla, -5.8 to -6.0 from the bregma. Sections were
then stained by Thioflavin S to detect amyloid plaques or
by AT8 monoclonal antibody (1:50; Pierce Biotechnology)
to detect neurofibrillary tangles.Thioflavin S staining
Thioflavin S staining was adapted from Westermark
et al. [44]. 0.5 gram Thioflavin S was dissolved in 50 mL
deionized water. The slides were immersed in Mayer’s
hematoxylin for 5 min and then washed under gently
running water for 5 min. The slides were placed into
the Thioflavin S solution for 5 min and subsequently
differentiated in 70% ethanol for 5 min. The slides were
rinsed in distilled water, mounted in glycerin jelly, and
stored in a dark chamber.
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For the quantification of plaques [13,45], two Thioflavin
S-stained serial sections per animal were used. For each
brain section, four fields which contained the highest
density of plaques were imaged and captured with a × 10,
numerical aperture 0.5 objective using an Axioskop 2 plus
ZEISS microscope (Carl Zeiss, Germany) with a fluores-
cein isothiocyanate filter (excitation at 488 nm). The total
pixel area of plaques for each section was counted using
SigmaScan Pro 5.0 software. The percentage plaque bur-
den was calculated by dividing the total area of plaques by
the total area of fields and multiplying by 100.
AT8 immunohistochemistry
NFTs were detected by immunohistochemistry using AT8,
a monoclonal antibody to a phosphorylated epitope on tau
[46,47]. Slides with brain sections were de-paraffinized and
rehydrated. Antigen retrieval was performed using citrate
buffer. Slides were rinsed by PBS, and peroxidase block
was applied. Slides were then blocked in 10% normal goat
serum, and AT8 (1:50) antibody was subsequently applied
and incubated overnight at room temperature.
Slides were rinsed with PBS, followed by incubation with
goat anti-mouse IgG for 45 minutes (Dako Envision +HRP,
Dako), and staining was developed using 3,3′-diaminoben-
zidine (DAB) peroxidase solution (Invitrogen). Slides
were rinsed with PBS and counterstained with Harris
Hematoxylin, dehydrated, and mounted.
Quantitation of tangles
Methods to quantitate tangles on stained sections were
adapted and modified from van Belle et al. and Zehr et al.
[45,48]. Quantitation of tangles in immunostained sections
was performed using the Axiovision 4 program. Only the
medulla region was examined. For each mouse, two sec-
tions were randomly selected across the whole medulla
and magnified by 40x under a microscope, and, for each
section, four photos were taken of the fields with the high-
est density of NFTs. Thus, there were eight photos per
mouse. SigmaScan Pro 5.0 software was used to detect
pixels of immunoreactivity in each photo. The colour
threshold was set manually to isolate the immunopositive
area. The percentage of tau immunopositivity was calcu-
lated by dividing immunopositive pixels of each photo by
the total number of pixels of the photo, giving one value
per photo. The eight values of each mouse were aver-
aged, giving one value per mouse. The software used
was Microsoft Office Excel 2007.
Statistical analysis
Results were analyzed by SPSS Statistics (Version 20).
P < 0.05 was considered statistically significant. Data were
presented in box plots with medians and interquartile
ranges. The effect of 17-AAG on mortality was analyzedby Fisher’s Exact Test. Since the sample size was small, the
data were not normally distributed, thus non-parametric
analyses were used. The Mann–Whitney U test was used
to analyze differences between treatment groups in total
plaque area and area occupied by NFTs. Linear mixed
models for longitudinal data were used to analyze the
average rotarod times before and after treatment.
Results
Motor function
The model revealed that the rotarod performance of un-
treated mice (dose = 0) dropped an average of 39.7 seconds
between before and after measurements (p = 0.0086).
Times of low dose mice rose an average of 1.6 seconds be-
tween before and after measurements, and this was
41.3 seconds better than untreated mice (p = 0.052; this is
the interaction p-value). Time of high dose mice dropped
an average of 15.6 seconds between before and after mea-
surements, and this was 24.2 seconds better than un-
treated mice (p = 0.22; this is the interaction p-value). The
overall dose x condition interaction p-value = 0.14; this is
the statistically most appropriate way to test the effective-
ness of the treatment given no a priori ideas about which
dose will work better. Thus, 17-AAG exhibited a tendency
to protect motor function in JNPL3 mice.
Mortality
Treatment began on 48 Tg2576 and 94 JNPL3 mice at age
eight months. Before treatment ended at age 11 months,
43% of mice died (Figure 1), however 17-AAG treatment
did not significantly affect the death rate of either Tg2576
(p = 0.24, Fisher’s Exact Test) or JNPL3 (p = 0.84, Fisher’s
Exact Test) mice. Autopsies were performed on some dead
mice, revealing accumulations of fluid in the abdominal
cavity and abnormal adhesions of intestines with mem-
branes and muscles near the lower flank. In mice treated
with 17-AAG, the fluid was purple or reddish-purple,
which is the color of 17-AAG in DMSO. Mice completing
three months of treatment received a cumulative intraperi-
toneal dose of DMSO of 7.8% (volume per body weight).
Aβ deposition
Of the 24 Tg2576 mice completing treatment, brains of 5
were excluded due to errors or problems processing the tis-
sue, and plaques were visualized in 19 mice by Thioflavin S
staining of amyloid (Figure 2). Treatment with 17-AAG
had no significant effect on the total plaque area (Mann–
Whitney test comparing control with combined low and
high dose: p = 0.97). Analyzing males and females separately
also revealed no treatment effect on plaque area.
Tau deposition
To quantify NFTs in JNPL3 mouse brains, immunohisto-
chemical staining was performed using the AT8 antibody,
Figure 1 Effect of 17-AAG on survival in JNPL3 and Tg2576 mice. For each dose of 17-AAG, number of mice surviving to the end of the
three-month treatment period at age 11 months or dying during treatment. Left: JNPL3 mice (tau transgenic). Right: Tg2576 mice (APP transgenic).
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appeared brown. Haematoxylin was used as a counterstain
of nucleic acid in cell nuclei.
The area occupied by NFTs did not differ between un-
treated mice (median area = 5.4%) and those receiving
17-AAG (either high or low doses; median area = 6.2%):
p = 0.84 (Mann–Whitney U test). Figure 3 suggests that
17-AAG did not affect the number of NFTs in female
mice, but that the highest dose may have reduced NFTs
in males. Figure 4 displays area occupied by NFTs for
each dose and sex. For males, Mann–Whitney U test
resulted in p = 0.08 for high dose vs. no 17-AAG.Figure 2 Effect of 17-AAG on amyloid plaques in Tg2576 mice.
Thioflavin S staining of amyloid plaques (green) in the hippocampus
of Tg2576 mice treated with different doses of 17-AAG: A) 0 mg/kg
(Control), B) 5 mg/kg, C) 25 mg/kg. Four fields of each dose
are shown.Discussion
Many mice in the study died during treatment. However,
mortality did not significantly differ between mice
treated with or without 17-AAG, thus 17-AAG was not
the cause of the high death rate. Perhaps repeated intra-
peritoneal injections, totaling 39 during the three month
study, killed mice due to needle injury. However, other
studies involving many intraperitoneal injections did not
report adverse health effects on mice.
Alternatively, DMSO, which was used as the vehicle to
dissolve 17-AAG, might have caused the deaths. As an ef-
fective solvent for a wide range of hydrophilic and hydro-
phobic compounds, DMSO readily penetrates animal tissue
and is widely used as a solvent in research [49]. At injection
sites, undiluted DMSO can irritate, inflame, and cause
intravascular thrombosis [50]. For mice that completed the
three month study, the cumulative dose of DMSO was
7.8% (v/w), quite a large proportion of body weight. Autop-
sies showed that the abdominal cavities of some of the mice
contained liquid, purple or reddish-purple for mice receiv-
ing 17-AAG and clear for control mice, and revealed ab-
normal adhesions between membranes and muscles, which
might have been caused by the solubilizing or inflammatory
effect of exposure to accumulations of DMSO. An add-
itional control group, using injections without either 17-
AAG or DMSO, could have helped explore whether DMSO
contributed to the early mortality we observed, however we
did not anticipate this problem and thus did not plan a
control group without DMSO.
DMSO was used because 17-AAG has limited water
solubility. A potential alternative is Cremophor EL, but it
may induce hypersensitivity reactions and anaphylaxis.
Thus, patients require treatment with steroids and antihis-
tamines before the administration of 17-AAG with Cremo-
phor EL. When 17-AAG was used in a phase II clinical trial
as an anti-tumour agent, only a limited effect of 17-AAG
against tumors was observed, perhaps due to DMSO tox-
icity [51]. Thus, another clinical trial was conducted using
Cremophor instead of DMSO, resulting in minimal toxicity
Figure 3 Effect of 17-AAG on neurofibrillary tangles in JNPL3 mice. AT8 immunostaining (brown) revealing NFTs in the medulla of JNPL3
mice treated with 17-AAG. Haematoxylin counterstain (blue) indicates cell nuclei. 40x magnification. Left: 0 mg/kg 17-AAG. Middle: 5 mg/kg 17-AAG.
Right: 25 mg/kg 17-AAG. Top two rows: Male mice. Bottom two rows: Female mice.
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be considered for future studies.
Treatment with 17-AAG tended to preserve motor
function in JNPL3 mice (p = 0.14), as measured by the
rotarod test. Whether this tendency represents a real effect
would require further studies, perhaps with a safer method
of administration, larger numbers of mice, longer treat-
ment, and treatment at different age ranges. It is possible
that treatment began too late or did not last long enough
to display effects to their greatest potential.
In this experiment, treatment with 17-AAG did not
reduce Aβ deposition in a transgenic mouse model of
Alzheimer’s disease. There are several possible expla-
nations for this lack of an effect.
We had hypothesized that 17-AAG could up-regulate
the expression of Hsp40 and Hsp70, which work synergis-
tically to disaggregate and degrade misfolded proteins, and
hence may suppress aggregation of Aβ. But 17-AAG had
limited ability to induce Hsp40 and Hsp70 in vivo [20,53].Induction of these heat shock proteins may have been
insufficient.
Another possibility is that Aβ may not be a Hsp90 client
protein. Hsp90 assists protein folding and stabilization of
its client protein, and 17-AAG is an Hsp90 inhibitor. Al-
though Hsp90 co-localized in vivo with amyloid filaments,
indicating that Hsp90 may have a role in either promoting
or suppressing the refolding of misfolded amyloid proteins
[17,54], the overall effect of Hsp90 on Aβ aggregation is not
clear. Since the action of Hsp90 is ATP-dependent, and
since the increase of reactive oxygen species induced by Aβ
may interfere with cellular mitochondrial energy metabol-
ism, thereby decreasing the supply of ATP [55], Aβ might
partially inhibit its own aggregation by inhibiting Hsp90.
When taking into account the possible contradictory effects
on protein aggregation, it is hard to predict whether 17-
AAG would raise or lower the level of protein aggregates.
Another possible reason may be that the mice were too
old when they began treatment. Inhibition of intracellular
Figure 4 Effect of 17-AAG on NFT area in JNPL3 mice. Area of
AT8 immunopositivity in the medulla of JNPL3 mice treated with
17-AAG. Boxes represent 25th and 75th percentiles; medians are the
lines across the boxes; whisker caps represent 5th and 95th percentiles;
and open circles are outliers. Doses of 17-AAG are shown as 0 mg/kg,
5 mg/kg, or 25 mg/kg. Top: Males. Bottom: Females.
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might not be effective to reverse extracellular aggregation
of Aβ once it has occurred. An earlier treatment may at-
tenuate the Aβ aggregation before pathology begins, but
mice of younger ages would be needed to test this.
Alternatively, the number of mice may have been in-
sufficient. Detection of a small treatment effect would
require many mice.
Finally, the method of quantification might have ob-
scured a treatment effect. By selecting the microscope
fields with the highest concentrations of plaques, a treat-
ment effect that decreased maximum or overall plaque
density would be detected, but an effect only on areas of
lower plaque density would be missed, as would an
effect on Aβ oligomers but not on plaques.
Tau is a member of the Hsp90 client protein family,
and mutant or hyperphosphorylated tau binds to Hsp90at high affinity compared with normal tau [32]; therefore,
theoretically, Hsp90 inhibitor might promote degradation
of hyperphosphorylated tau and hence reduce neurotox-
icity and decrease NFT formation. However, among all
mice in our study, 17-AAG did not significantly reduce
tau deposition.
As for NFT quantification, the method used to quantify
NFTs might have obscured a treatment effect. By selecting
the microscope fields with the highest concentrations of
NFTs, a treatment effect that decreased overall or max-
imum NFT density would be detected, but an effect only
on areas of lower NFT density would be missed, as would
an effect on tau oligomers but not on NFTs. Quantifying
total tau rather than only hyperphosphorylated tau may
also have provided additional data, however hyperpho-
sphorylated tau is a marker of dysfunction and aggregation
in tauopathies and is thus more informative.
It is notable that, although 17-AAG did not decrease
NFTs when all mice were examined together, when mice
were analyzed by sex, male but not female mice exhibited
a tendency toward a decrease in NFTs with the high dose
of 17-AAG. A possible explanation could be that female
JNPL3 mice tend to develop phenotypic features earlier
than male JNPL3 mice, as found in previous research [56]
and in the current study, in which 11-month old female
mice displayed more NFT than did males of the same age.
Sex differences have also been found in other amyloidoses
[57-59]. If treatment with 17-AAG is effective at early
stages of tauopathy, it would be more beneficial in male
than female mice of the same age. A possible explanation
for the difference in tauopathy progression between male
and female mice is the difference in hormonal states. The
primary female steroid sex hormones are estrogens, which
occur as three types: estrone, estradiol, and estriol, of
which estradiol is the most potent. Numerous studies, in-
cluding both human and animal, have shown that estro-
gens can be neuroprotective and neurotrophic [60-62],
though studies also suggest estrogens may either reduce
or increase AD risk [63]. Estradiol can decrease tau phos-
phorylation [64]. Yet female JNPL3 mice display more
NFTs than males of the same age. The mechanism for this
difference remains unknown.
Luo et al. [34] tested the effect of an Hsp90 inhibitor on
tau reduction, both in vitro and in vivo. As in the present
study, they used Hsp90 inhibitors and JNPL3 mice. Their
mice were heterozygous females aged 6.5 months, treated
five times per week for 30 days. The Hsp90 inhibitors,
PU24FC1 and PU-DZ8, reduced tau expression and phos-
phorylation (p = 0.0034). The team concluded that Hsp90
inhibitors can prevent and reverse tau aggregation. How-
ever, we found no effect of Hsp90 inhibition on tau path-
ology in female JNPL3 mice. Differences in the mice
between the two studies might explain the discrepancy.
The Luo mice had milder pathology because they were
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expressed less mutant tau (hemizygous vs. homozygous).
Consistent with our finding of a tendency toward a protect-
ive effect of 17-AAG in the subset of mice with milder
pathology—males—the drug might be useful against tauo-
pathies at early stages of disease. Further studies may ex-
plore this possibility.
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